BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Chris Joneckis Of Center For Biologics Evaluation And Research, FDA To Present At IBC Life Sciences' Early Development Of Biotherapeutics Event


10/19/2005 5:10:37 PM

WESTBOROUGH, Mass., March 30 /PRNewswire/ -- IBC's Inaugural Early Development of Biotherapeutics event to be held April 26-28, 2004 at the Sheraton San Diego Hotel & Marina in San Diego, CA will feature Chris Joneckis, Ph.D., Senior Advisor for Chemistry Manufacturing and Control Issues, Office of the Director, CBER, FDA presenting on the FDA's Perspective for Comparability. This event, having an unrivaled list of featured presenters, focuses on successful approaches for managing immunogenicity and comparability, interpreting regulations and guidances, and implementing process changes.

Anthony R. Mire-Sluis, Ph.D., Principal Advisor for Regulatory Science and Review, CDER, US FDA will give an Update on Regulatory and Industry Perspectives on the Design and Optimization of Immunogenicity Assays. This will be part of a day of programming on Biological Assays & Development. Early Development of Biotherapeutics attendees and Biological Assay Development & Validation attendees will share a day of sessions which will feature 5 case studies, a luncheon, and a cocktail reception, creating a rare opportunity to share perspectives and strategies with hundreds of leaders in the industry.

Other highlights will include; Case studies on Recombinant Factor VIII, ENBREL(R) and Avastin; ICH guidelines for product quality, stability, methods validation, and cell line characterization; Novel approaches to cell line development; Impact of reversible protein self association on manufacturing, formulation and delivery of protein pharmaceuticals; and Strategies and opportunities for fast tracking and accelerated approval.

Attendees will walk away with the ability to accelerate the development of their recombinant therapeutic protein program by understanding the current industry and regulatory approaches to preclinical, clinical and product development of biotherapeutics.

  Scientific Advisory Committee:

  -- Jeanne M. Novak, Ph.D., Principal Consultant, CBR International Corp.
     (Lead Advisor)
  -- Fred G. Bader, Ph.D., Vice President, Process Sciences, Centocor
  -- John F. Carpenter, Ph.D., Co-Director, Center for Pharmaceutical
     Biotechnology, University of Colorado Health Sciences Center
  -- Eric Wakshull, Ph.D., Principal Scientist, Biogen Idec Inc.


ATTENTION CALENDAR EDITORS! For more information on attending Early Development of Biotherapeutics at the Sheraton San Diego Hotel & Marina - West Tower, in San Diego, CA visit http://www.lifesciencesinfo.com/3071

CONTACT: Kerry Patterson

EMAIL: kpatterson@ibcusa.com

IBC

CONTACT: Kerry Patterson, IBC, kpatterson@ibcusa.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->